Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids

OBJECTIVE: To assess outcomes of women with uterine fibroids (UFs) and heavy menstrual bleeding (HMB) treated with 300 mg elagolix twice daily plus add-back therapy (E2 1 mg/NETA 0.5 mg once daily) or placebo who were not considered responders in pooled analysis of two phase 3, 6-month randomized cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Stewart, Elizabeth A., Archer, David F., Owens, Charlotte D., Barnhart, Kurt T., Bradley, Linda D., Feinberg, Eve C., Gillispie-Bell, Veronica, Imudia, Anthony N., Liu, Ran, Kim, Jin Hee, Al-Hendy, Ayman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133968/
https://www.ncbi.nlm.nih.gov/pubmed/34582715
http://dx.doi.org/10.1089/jwh.2021.0152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133968/
https://www.ncbi.nlm.nih.gov/pubmed/34582715
http://dx.doi.org/10.1089/jwh.2021.0152

Ejemplares similares